Therapeutic Solutions International Expands Chronic
Traumatic Encephalopathy Intellectual Property
Portfolio
New Data Demonstrates Ability of Immune System to Alter
Football Related Brain Injuries
OCEANSIDE, CA
-- December
06, 2018 --
InvestorsHub NewsWire -- Therapeutics
Solutions International, Inc., (OTC Markets:
TSOI) announced
today
data demonstrating that modification of certain elements of the
immune response can alter brain function in models of Chronic
Traumatic Encephalopathy (CTE).
The Company filed a
patent covering the use of specific molecules which activate parts
of the immune system, which are usually associated with suppressing
brain function, as a means of protecting from injury associated
with multiple hits to the brain. The data is
very
contradictory to what is expected, and
therefore, in the opinion of the Company, likely to result in
issuance of the patent that was filed.
"It is widely
recognized that immune modulation is a mechanism by which many
interventions in the area of neurology work. For example, in animal
models, removal of immune organs abrogates the
ability
of stem cells and their soluble mediators to ameliorate the
neurological impact of stroke1"
said Thomas Ichim,
Board Member of the Company and Co-Inventor of the
Patent. "It is not a coincidence, in my opinion, that out of all
the systems of the body, only the immune system, and the nervous
system possess memory, self, non-self-recognition,
and
the
ability
to possess specificity to an extremely high degree."
The Company, through
its academic collaborators, demonstrated not only ability of
mesenchymal stem cells to reverse chronic traumatic encephalopathy
in animal models, but observed the very paradoxical finding that
treating the stem cells with chemicals associated with brain
damage, endows enhanced therapeutic activity to the stem
cells.
"The current data, in
my opinion, is
very
rational. If stem cells were constantly
active,
they would be expending energy for nothing" said
Dr.
James
Veltmeyer, Chief Medical Officer of the Company. "It is
conceptually logical that by exposing stem cells to molecular
signals which mimic
injury,
that the stem cells will possess
enhanced
therapeutic activity."
By stimulating the
TLR3 arm of the immune system and demonstrating reduction of brain
damage subsequent to multiple sub-acute chronic injuries, but not
in single acute injuries such as stroke, the Company believes it
has identified major differences between the chronic traumatic
encephalopathy which occurs in sports (which is many small hits
over time), in contrast to traumatic brain injury or situations in
which one major event leads to brain damage.
"We are in an ideal
position in that our NeuroStilbene product, appears to
possess prophylactic properties, and we are currently working on
therapeutic approaches to the problem of Chronic Traumatic
Encephalopathy," said Tim Dixon CEO of
the Company and
Co-Inventor. "These sub-acute
brain injuries are not only associated with NFL football players
but also our military, which in some cases predisposes
them
to
PTSD2."
About
Therapeutic Solutions International, Inc.
Therapeutic Solutions
International is focused on immune modulation for the treatment of
several specific diseases. Immune modulation refers to the ability
to upregulate (make more active) or downregulate (make less active)
one's immune system. The Company's corporate website is
www.therapeuticsolutionsint.com.
These statements have
not been evaluated by the Food and Drug Administration. These
products are not intended to diagnose, treat, cure, or prevent any
disease.
1
Venkat et
al. https://www.ncbi.nlm.nih.gov/pubmed/29888985 2018
Dec;38(12):2165-2178.
2
Omalu et
al. https://www.ncbi.nlm.nih.gov/pubmed/22044102 2011
Nov;31(5):E3.
Safe Harbor
Statement
This release contains
forward-looking statements that are based upon current expectations
or beliefs, as well as a number of assumptions about future events.
Although we believe that the expectations reflected in the
forward-looking statements and the assumptions upon which they are
based are reasonable, we can give no assurance that such
expectations and assumptions will prove to have been correct.
Forward-looking statements are generally identifiable by the use of
words like "may," "will," "should," "could," "expect,"
"anticipate," "estimate," "believe," "intend," or "project" or the
negative of these words or other variations on these words or
comparable terminology. The reader is cautioned not to put undue
reliance on these forward-looking statements, as these statements
are subject to numerous risk factors as set forth in our SEC
filings. To the extent that statements in this press release are
not strictly historical, including statements as to product launch
timing, revenue projections, business strategy, outlook,
objectives, future milestones, plans, intentions, goals, future
collaboration agreements, or otherwise as to future events, such
statements are forward-looking, and are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. The forward-looking statements contained in this release
are subject to certain risks and uncertainties that could cause
actual results to differ materially from the statements
made.
CONTACT
INFORMATION
Therapeutic Solutions (PK) (USOTC:TSOI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Therapeutic Solutions (PK) (USOTC:TSOI)
Historical Stock Chart
From Apr 2023 to Apr 2024